Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Info for
    • Authors
    • Reviewers
  • About Us
    • About Us
    • Conflict of Interest
    • Informed Consent
    • Human and Animal Rights
  • More
    • Alerts
    • Feedback
    • Folders
  • ascls.org
    • ascls.org

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society for Clinical Laboratory Science
  • ascls.org
    • ascls.org
  • My alerts
  • Log in
  • My Cart
American Society for Clinical Laboratory Science

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Info for
    • Authors
    • Reviewers
  • About Us
    • About Us
    • Conflict of Interest
    • Informed Consent
    • Human and Animal Rights
  • More
    • Alerts
    • Feedback
    • Folders
  • Follow ASCLS on Twitter
  • Visit ASCLS on Facebook
  • Follow ASCLS on Instagram
  • RSS Feed
Research ArticleFocus: Blood Cell Malignancies

Malignancy: An Evolving Definition of a Cancer Cell

J Lynne Williams
American Society for Clinical Laboratory Science January 2002, 15 (1) 37-43; DOI: https://doi.org/10.29074/ascls.15.1.37
J Lynne Williams
is Professor, Medical Laboratory Sciences School of Health Sciences, Oakland University, Rochester MI
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: lynnew@umich.edu jlwillia@oakland.edu
  • Article
  • Info & Metrics
  • PDF
Loading

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

  1. J Lynne Williams, PhD⇑
    1. is Professor, Medical Laboratory Sciences School of Health Sciences, Oakland University, Rochester MI
  1. Address for correspondence: J Lynne Williams Professor, Med Lab Sciences, Oakland University, Rochester MI 48309. (734) 647-2898 or (248) 370-4040. lynnew{at}umich.edu or jlwillia{at}oakland.edu
  1. Compare and contrast the functional characteristics of oncogenes and tumor suppressor genes.

  2. Summarize the four broad functional categories of oncogenes.

  3. Define and explain the role of cyclins and Cdks in regulating cell cycle progression.

  4. Describe the ‘cell-cycle checkpoints’.

  5. Explain how loss of Rb protein can contribute to oncogenesis.

  6. Summarize the roles of caspases, the Bcl-2 family of proteins, and IAPs (inhibitors of apoptosis) in the regulation of apoptosis.

  7. Correlate overexpression of Bcl-2 and Bcl-XL, or loss of function of p16 or p27, with oncogenesis.

  8. Describe the role of telomerase in tumorigenesis.

Extract

In recent years there has been an explosive growth in our understanding of cancer cell biology. For most of the 20th century, cancer was assumed to be a disease of uncontrolled proliferation of cells. A (malignant) neoplasm was defined as ‘an abnormal mass of cells typically exhibiting uncontrolled and progressive growth’.1 A more current definition of malignancy recognizes the complex interplay of an imbalance between cell proliferation, differentiation, and cell death.2 The molecular mechanisms regulating cell proliferation and cell death (apoptosis) have been among the areas of biomedical research generating intense interest for the past 20 years. As these molecular controls have been defined and refined, our understanding of the molecular basis of malignancy has similarly been advanced, and new diagnostic and therapeutic approaches for various human malignancies are being developed.

ONCOGENES AND TUMOR SUPPRESSOR GENES Cancer is a genetic disease. The characteristics that make a cell malignant are stably inherited during the process of cell division. We also recognize that most tumors are clonally derived from a single common progenitor cancer cell that typically divides to generate a tumor of identical sibling cells. Together, these two observations indicate that the disease phenotype is determined by the tumor cell DNA.

A major advancement in understanding cancer cell biology was the discovery that certain viruses, when inoculated into animals, had the capacity to cause the development of tumors. This critically important observation resulted in a massive investigation to identify the particular viral genes capable of inducing malignant transformation. The tumor-causing viruses…

ABBREVIATIONS: Cdk = cyclin-dependent kinases; PTK = protein-tyrosine kinases.

    INDEX TERMS
  • malignancy
  • tumor
  1. Compare and contrast the functional characteristics of oncogenes and tumor suppressor genes.

  2. Summarize the four broad functional categories of oncogenes.

  3. Define and explain the role of cyclins and Cdks in regulating cell cycle progression.

  4. Describe the ‘cell-cycle checkpoints’.

  5. Explain how loss of Rb protein can contribute to oncogenesis.

  6. Summarize the roles of caspases, the Bcl-2 family of proteins, and IAPs (inhibitors of apoptosis) in the regulation of apoptosis.

  7. Correlate overexpression of Bcl-2 and Bcl-XL, or loss of function of p16 or p27, with oncogenesis.

  8. Describe the role of telomerase in tumorigenesis.

  • © Copyright 2002 American Society for Clinical Laboratory Science Inc. All rights reserved.
PreviousNext
Back to top

In this issue

American Society for Clinical Laboratory Science: 15 (1)
American Society for Clinical Laboratory Science
Vol. 15, Issue 1
Winter 2002
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on American Society for Clinical Laboratory Science.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Malignancy: An Evolving Definition of a Cancer Cell
(Your Name) has sent you a message from American Society for Clinical Laboratory Science
(Your Name) thought you would like to see the American Society for Clinical Laboratory Science web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Malignancy: An Evolving Definition of a Cancer Cell
J Lynne Williams
American Society for Clinical Laboratory Science Jan 2002, 15 (1) 37-43; DOI: 10.29074/ascls.15.1.37

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Malignancy: An Evolving Definition of a Cancer Cell
J Lynne Williams
American Society for Clinical Laboratory Science Jan 2002, 15 (1) 37-43; DOI: 10.29074/ascls.15.1.37
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • The New WHO Nomenclature: Introduction and Myeloid Neoplasms
  • The New WHO Nomenclature: Lymphoid Neoplasms
Show more Focus: Blood Cell Malignancies

Similar Articles

Keywords

  • malignancy
  • tumor

© 2025 The American Society for Clinical Laboratory Science

Powered by HighWire